JMP Securities Upgrades BioCryst Pharma (BCRX) to Market Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/17/2026
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Oil touches $110 a barrel for first time since May on Middle East, Russia supply fears
- Stay risk-off as higher real yields and AI volatility threaten stocks: BofA
- Apple’s first foldable iPhone sells out within minutes as preorders begin
- CoreWeave bond rout tests market's math on AI buildout
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $7.79 -2.87%
Rating Summary:
16 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 22 | New: 41
Rating Summary:
16 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 22 | New: 41
Join SI Premium – FREE
JMP Securities upgraded BioCryst Pharma (NASDAQ: BCRX) from Market Perform to Market Outperform with a price target of $3.00.
For an analyst ratings summary and ratings history on BioCryst Pharma click here. For more ratings news on BioCryst Pharma click here.
Shares of BioCryst Pharma closed at $2.04 yesterday.
For an analyst ratings summary and ratings history on BioCryst Pharma click here. For more ratings news on BioCryst Pharma click here.
Shares of BioCryst Pharma closed at $2.04 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James Upgrades Capri Holdings (CPRI) to Strong Buy, Adds to Analyst Current Favorite List
- Goldman Sachs Upgrades Zeta Global Holdings Corp (ZETA) to Buy
- Barrington Research Upgrades Opko Health (OPK) to Outperform
Create E-mail Alert Related Categories
Hot Upgrades, UpgradesRelated Entities
JMP SecuritiesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
